Form 8-K - Current report:
SEC Accession No. 0001437749-25-019718
Filing Date
2025-06-06
Accepted
2025-06-06 16:07:02
Documents
15
Period of Report
2025-06-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K aytu20250523c_8k.htm   iXBRL 8-K 35299
2 EXHIBIT 99.1 ex_823251.htm EX-99.1 27612
7 logo01.jpg GRAPHIC 3651
  Complete submission text file 0001437749-25-019718.txt   213286

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aytu-20250605.xsd EX-101.SCH 3578
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aytu-20250605_def.xml EX-101.DEF 11423
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aytu-20250605_lab.xml EX-101.LAB 15309
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aytu-20250605_pre.xml EX-101.PRE 11583
17 EXTRACTED XBRL INSTANCE DOCUMENT aytu20250523c_8k_htm.xml XML 2845
Mailing Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237
Business Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 251030642
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)